Immunology

Dualyx: restoring the body’s balance in autoimmune diseases

Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The […] May 12, 2022 · V-Bio Ventures

miDiagnostics launches its CE-IVD certified ultra-fast COVID-19 PCR test

Leuven, Belgium, 2 May 2022 – miDiagnostics, a fast-growing POC diagnostics company announces the launch of its CE-IVD certified ultra-fast COVID-19 PCR […] May 2, 2022 · Turnstone Communications

Abscint labels antibodies with radioactive material to spot harmful cells

Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies […] March 16, 2022 · BioVox

Long COVID: what it means for the life sciences industry and other chronic conditions

Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although […] December 15, 2021 · V-Bio Ventures

Saving kidneys with a test that improves early detection of transplant rejection

All too often, kidney transplants fail because signs of a possible rejection remained unnoticed for too long. That’s why Belgian […] December 15, 2021 · BioVox

New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster

Ghent, Belgium, 6 December 2021 – Trince, a spin-off of Ghent University (UGent), is developing innovative and efficient technology to insert […] December 6, 2021 · Turnstone Communications

Confo-dently into the future!

Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, […] November 24, 2021 · V-Bio Ventures

EsoBiotec ready to transform cell therapy cancer treatments

– EsoBiotec, a recently founded biotech company, announces a EUR 6 million pre-series A round comprised of non-dilutive funding from […] September 30, 2021 · Turnstone Communications

Moderna: from secretive platform company to vaccine superstar

Moderna Therapeutics has never really been a typical biotech. Sure, nowadays it is world famous thanks to its COVID-19 vaccine, […] June 23, 2021 · V-Bio Ventures

Malaria vaccine candidate shows promise for African children

Despite decades of research, scientists have so far been unable to develop a fully effective vaccine for malaria. Now, a […] June 16, 2021 · BioVox

Record-breaking pollen levels linked to increased risk of COVID-19

Increased pollen concentrations are correlated with higher rates of COVID-19. Hot on the heels of record-breaking European pollen counts, this […] March 10, 2021 · BioVox

Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center

– Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk […] February 8, 2021 · Turnstone Communications

One year of COVID-19: a look back at 2020 and where we are now

One year on from the emergence of SARS-COV-2 in Wuhan, China, this novel coronavirus continues to devastate the world. Since […] January 27, 2021 · BioVox

Decades-old discoveries cause paradigm shifts in modern medicine

Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. […] December 16, 2020 · V-Bio Ventures

Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers

Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe […] December 1, 2020 · Turnstone Communications

Vascular dysfunction meets immune suppression

November 4, 2020 · BioVox

Montis Biosciences appoints Karen Zinkewich-Péotti as Chief Executive Officer

Leuven, Belgium, 29 September 2020 – Montis Biosciences, a discovery stage biotech company focused on novel immuno-oncology therapeutics targeting the […] September 29, 2020 · Turnstone Communications

Countering COVID-19 with llama antibodies

In July 2020, VIB spin-off ExeVir Bio raised €23 million to advance a llama-derived antibody against COVID-19. The company is […] August 31, 2020 · BioVox

A novel approach to neurology could bring relief to people in pain

In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio Ventures

Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures

Newton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases

Brussels, Belgium / Tokyo, Japan – 27 August 2020 – Newton Biocapital I (“Newton”), an investment company in life sciences, […] August 27, 2020 · Turnstone Communications

To prevent another pandemic, we need to improve our relationship with animals

The new coronavirus did not come as a bolt from the blue. For many years, the World Health Organization (WHO) […] June 8, 2020 · BioVox

Fundamental research leads to treatment breakthrough in rare genetic diseases

A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing […] June 8, 2020 · BioVox

Talking T cells with David Masopust

Immunology is a complex but vitally important branch of the life sciences. Earlier this year, we attended a Keystone Symposia […] June 8, 2020 · BioVox

New immune system gene discovered in a Flemish boy

Researchers studying a rare disease have identified a new gene responsible for human immune system regulation. An international collaboration combined […] November 26, 2019 · BioVox

Fresh insights into the future of cell therapy

The first edition of Science for health was held in the heart of Brussels on September 11 with a focus […] September 23, 2019 · BioVox

Galapagos-Gilead billion-dollar deal: beyond the numbers

Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a […] August 27, 2019 · BioVox

Living on the edge: the challenge of doing things differently in cell therapy

Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even […] July 17, 2019 · BioVox

Edible antibodies to prevent and treat gut diseases

Belgian researchers have developed edible antibodies that can prevent gut bacterial infections. Normally antibodies need to be injected, but the […] June 27, 2019 · BioVox

Miracle microchips improving cell therapy manufacturing

A microchip engineer might seem like an odd fit for a keynote speaker at an event focused on cell therapy, but at Science for health Peter Peumans will [...] June 14, 2019 · BioVox

A microbiome solution for type 1 diabetes?

Few things unite us the way trying to help a sick child does. Children living with the burden of type […] December 14, 2018 · Janssen Pharmaceutica

argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody […] December 4, 2018 · Turnstone Communications

Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018

Dr. James Allison has dedicated his career to improving our fundamental understanding of how the adaptive immune system works. Much […] September 18, 2018 · Janssen Pharmaceutica

Uncovering the secrets of inflammasomes

Mohamed (Mo) Lamkanfi made the jump from academia to industry a mere eight months ago, to pursue a career with […] August 21, 2018 · Janssen Pharmaceutica

New beta cell antigens discovered in Type 1 diabetes

A study published just last week has unveiled several new antigens implicated in Type 1 diabetes. In an ongoing project, […] August 7, 2018 · Turnstone Communications

Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. The […] July 31, 2018 · BioVox

Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 […] July 3, 2018 · BioVox

Curing hay fever - ASIT Biotech allergy vaccines

The sun is shining, the grass is green, but hay fever season is at its peak! Many people (myself included) will spend a lot of money on antihistamines and [...] June 12, 2018 · Turnstone Communications

UCB psoriasis drug approved for use in mothers

The UCB core drug CIMZIA® has just been approved by European Medicines Agency (EMA) for use in pregnant and breastfeeding […] March 19, 2018 · Turnstone Communications

Caitlin Gillis at VIB - Foreign Scientist in Belgium

Caitlin Gillis left the sunshine and warmth of Australia a few years ago to come live Europe. After a stint […] March 18, 2018 · BioVox

The biggest killer after malaria - How to tackle RSV?

Respiratory syncytial virus (RSV) annually threatens many babies and there is currently no drug or vaccine to combat the disease. […] February 19, 2018 · Turnstone Communications

Celyad: CAR-T cells with natural killer skills fight cancer

Celyad, based in Mont-Saint-Guibert (Belgium), was originally established in 2004 as a company active in regenerative cell therapy. However, two […] January 9, 2018 · Turnstone Communications

Curing coughs: understanding the development of asthma using dust mites

Winter is upon us and many people will be suffering from colds and coughs. However, very few of these coughs […] December 18, 2017 · BioVox

Vaccinating against cancer with dendritic cells

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain [...] November 12, 2017 · Turnstone Communications

Diagnosed with lung cancer

A patient diagnosed with lung cancer should brace for the worst. Prognosis is often very disappointing. While in many cancers […] October 16, 2017 · Turnstone Communications

Very promising cancer treatment: RNAi immunotherapy

RXi Pharmaceuticals was co-founded by Craig Mello, PhD, the co-recipient of the 2006 Nobel Prize in Medicine for the discovery […] October 10, 2017 · BioVox

ImmunXperts: your partner for in vitro assays in cancer immunotherapy

Although immunotherapy in cancer is booming, it isn’t by any measure an easy field to navigate. Many oncology ventures willing to explore this new terrain [...] October 9, 2017 · Turnstone Communications

Dendritic cells boosted with mRNA form promising cancer immunotherapy

With its expertise in mRNA production and knowledge of the biology of dendritic cells, eTheRNA has developed TriMix, a new […] September 11, 2017 · Turnstone Communications

IDO 1: a promising new target for immunotherapy

iTeos Therapeutics started in 2012 as a spin-off from the Ludwig Institute for Cancer Research (LICR), one of the top […] June 12, 2017 · Turnstone Communications

Immunotherapy: a paradigm shift in cancer treatment

An excerpt from the BioVox White paper on Cancer Immunotherapy.

June 12, 2017 · BioVox

Lars Klareskog pushes rheumatology beyond symptomatic treatment

Over the years, the perception of inflammatory diseases has changed drastically. The advent of cytokine inhibitors meant great improvement to many patients, especially those suffering from rheumatoid arthritis. However, these treatments remain symptomatic. Together with Janssen Pharmaceutica, world-renowned rheumatologist Lars Klareskog is ready to take the research and treatment of inflammatory joint disease to the next level.

June 12, 2017 · Janssen Pharmaceutica

Macrophages to protect you from asthma

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation and propose to use this discovery to set up a strategy of cell therapy to treat asthma in humans. Their discovery is published in Immunity.

April 17, 2017 · Turnstone Communications